(Q38223292)

English

Experimental trials in amyotrophic lateral sclerosis: a review of recently completed, ongoing and planned trials using existing and novel drugs

scientific article published on 26 June 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Experimental trials in amyotrophic lateral sclerosis: a review of recently completed, ongoing and planned trials using existing and novel drugs (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

amyotrophic lateral sclerosis

0 references

author name string

Namita A Goyal

1

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Tahseen Mozaffar

2

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

language of work or name

0 references

publication date

26 June 2014

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Expert Opinion on Investigational Drugs

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

23

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

1541-1551

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Neuroprotective effects of lithium in cultured cells and animal models of diseases.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Lithium down-regulates tau in cultured cortical neurons: a possible mechanism of neuroprotection.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Lithium delays progression of amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Lithium induces autophagy by inhibiting inositol monophosphatase

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

AMPA receptor-mediated slow neuronal death in the rat spinal cord induced by long-term blockade of glutamate transporters with THA.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Impaired glutamate uptake and EAAT2 downregulation in an enterovirus chronically infected human glial cell line.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Selective loss of glial glutamate transporter GLT‐1 in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Altered expression of the glutamate transporter EAAT2b in neurological disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Crosstalk between astrocytes and motor neurons: what is the message?

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

The AMPA receptor antagonist NBQX prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

A crossover, add-on trial of talampanel in patients with refractory partial seizures

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Protection from fatal viral encephalomyelitis: AMPA receptor antagonists have a direct effect on the inflammatory response to infection

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Beta-lactam antibiotic offers neuroprotection in a spinal muscular atrophy model by multiple mechanisms

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

A beta-lactam antibiotic dampens excitotoxic inflammatory CNS damage in a mouse model of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

The beta-lactam antibiotic, ceftriaxone, dramatically improves survival, increases glutamate uptake and induces neurotrophins in stroke

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

State of play in amyotrophic lateral sclerosis genetics

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Gene-targeted therapies for the central nervous system

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Antisense oligonucleotide therapy for neurodegenerative disease.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-Lpropylamino-benzathiazole dihydrochloride].

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Safety, tolerability, and pharmacokinetics of KNS-760704 (dexpramipexole) in healthy adult subjects.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Upregulation of heat shock proteins rescues motoneurones from axotomy-induced cell death in neonatal rats

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

The role of heat shock proteins in Amyotrophic Lateral Sclerosis: The therapeutic potential of Arimoclomol

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Neuroprotective effects of mexiletine on motor evoked potentials in demyelinated rat spinal cords

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Comparative neuroprotective effect of sodium channel blockers after experimental spinal cord injury.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Do sodium channel blockers have neuroprotective effect after onset of ischemic insult?

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Mutant SOD1-expressing astrocytes release toxic factors that trigger motoneuron death by inducing hyperexcitability

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Nogo provides a molecular marker for diagnosis of amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

The neurite outgrowth inhibitor Nogo-A promotes denervation in an amyotrophic lateral sclerosis model

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trial

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Peripheral nerve inflammation in ALS mice: cause or consequence

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Macrophage colony stimulating factor (M-CSF) exacerbates ALS disease in a mouse model through altered responses of microglia expressing mutant superoxide dismutase.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Rasagiline is neuroprotective in a transgenic model of multiple system atrophy

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

The delayed-start study in Parkinson disease: can't satisfy everyone

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Role of mitochondria in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Research advances in amyotrophic lateral sclerosis, 2009 to 2010.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology, Management and Therapeutic Trials

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Human neural stem cell grafts ameliorate motor neuron disease in SOD-1 transgenic rats

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Human neural stem cell grafts in the spinal cord of SOD1 transgenic rats: differentiation and structural integration into the segmental motor circuitry

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Dual transplantation of human neural stem cells into cervical and lumbar cord ameliorates motor neuron disease in SOD1 transgenic rats

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Host induction by transplanted neural stem cells in the spinal cord: further evidence for an adult spinal cord neurogenic niche

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis: results of a phase I trial in 12 patients.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: phase 1 trial outcomes.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Stem cell technology for the study and treatment of motor neuron diseases.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Concise review: Stem cell therapies for amyotrophic lateral sclerosis: recent advances and prospects for the future

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Intracerebroventricular injection of encapsulated human mesenchymal cells producing glucagon-like peptide 1 prolongs survival in a mouse model of ALS.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Mesenchymal stem cells and the treatment of conditions and diseases: the less glittering side of a conspicuous stem cell for basic research

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Subcutaneous IGF-1 is not beneficial in 2-year ALS trial

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Multipoint incremental motor unit number estimation as an outcome measure in ALS.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

The use of statistical MUNE in a multicenter clinical trial

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: clinical, neuroimaging, and hormonal results.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

G-CSF prevents the progression of structural disintegration of white matter tracts in amyotrophic lateral sclerosis: a pilot trial

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Electrical impedance myography as a biomarker to assess ALS progression

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Autophagy and amyotrophic lateral sclerosis: The multiple roles of lithium

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Madras motor neuron disease: Crossing borders

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.933807

21 January 2018

Identifiers

10.1517/13543784.2014.933807

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38223292&oldid=1748173155"